Galapagos’ R&D Roundtable showcases Toledo program - Seite 4

Nachrichtenquelle: globenewswire
27.10.2020, 16:21  |  140   |  0   |   

Diesen Artikel teilen
Seite 4 von 3
Wertpapier


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Galapagos’ R&D Roundtable showcases Toledo program - Seite 4 Comprehensive preclinical package elucidates dual mode of action (MoA) and potential broad applicability of salt-inducible kinase (SIK) inhibitors in inflammationInnovative chemistry generated multiple series of SIK compounds with distinct …

Nachrichten des Autors

Titel
Clean Power Capital Announces Appointment of Former Shell Oil Products US Executive David Bray to ...
Blockchain Foundry Announces CAD$10 Million Private Placement with Institutional Investors
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento ...
Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their ...
Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder ...
Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for ...
Changes in the Supervisory Board of Inbank AS
Bavarian Nordic Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of ...
BGHL GBP NAV & Share buy back
Titel
Norsk Hydro: Hydro agrees to sell Rolling business area to KPS Capital Partners for EUR 1,380 million
Emerging Markets Report: Expand the Brand
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results ...
CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for ...
Hunter Technology Market Testing Pilot April Launch
CytoDyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital ...
Algernon Pharmaceuticals Announces Private Placement
Bitfarms Announces Purchase Agreement for 48,000 MicroBT Miners to Expand Hash Rate Capacity by ...
Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in ...
BIGG Digital Assets Inc. Announces Grant of Stock Options
Titel
Spineway Expansion in Asia
Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to ...
SPINEWAY: NEW BUSINESS AGREEMENT DEDICATED TO 3D INNOVATION
American Lithium Reaches Agreement to Acquire Plateau Energy Metals and Consolidate ...
REPEAT --TAAT E-Commerce Launching Wednesday February 17, Availing Original, Smooth, and Menthol to ...
Emerging Markets Report: One + One = Three
Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock
EHang Responds to Deceptive Wolfpack Research Report
Seeking Alpha Blog Post Details Growth of Alternatives to Incumbent CPG Products in February 11 ...
European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product ...
Titel
Spineway Expansion in Asia
AgraFlora Organics Expects to Enter Edibles Market in Q1
HyperSolar Changes Company Name to SunHydrogen
Halo Announces Pricing of Overnight Marketed Offering of Units
WPD Pharmaceuticals to Resume Trading on Monday, April 13, 2020
Bombardier unterzeichnet Vertrag für weitere zehn Jahre Betrieb und Wartung des automatischen ...
Ocugen and Bharat Biotech to Co-Develop COVAXIN, a Whole-Virion Inactivated COVID-19 Vaccine, for ...
HyperSolar To Begin Production on 100 Hydrogen Generation Units for Demonstration
Mateon Expands its COVID-19 Therapeutic Program to include Artemisinin
Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of ...

Nachrichten zu den Werten

ZeitTitel
04.03.21
GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES
03.03.21
Transparency notification received from The Capital Group
18.02.21
Pipeline and capital for growth
10.02.21
Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
10.02.21
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF
09.02.21
The Capital Group holds 10.03% of Galapagos shares

COMMUNITY

ZeitTitel
19.08.20
155
Galapagos NV